Less than a third of ED visits for acute sickle cell disease pain were guideline-adherent for the timely administration of ...

Motixafortide alone and in combination with natalizumab can support the collection of the large number of stem cells required ...

Sickle cell disease causes excruciating pain and damage to the body. But now there are new treatments that can put an end to ...

Iron overload is prevalent among adults with sickle cell disease (SCD), according to a study presented at the annual meeting ...

Adding erythropoietin to hydroxyurea treatment could significantly improve quality of life for patients with sickle cell ...

Cambridge-based Fulcrum Therapeutics said it will aim to launch a large clinical trial in the second half of 2026 to prove ...

At ASH 2025, Fulcrum presented promising data on a sickle cell pill and Incyte is pioneering a new way to treat myelofibrosis ...

Cellarity, a clinical-stage biotechnology company developing Cell State-Correcting therapies through integrated multi-omics and AI modeling, today announced the presentation of new preclinical data on ...

Only 1 in 3 patients in an ER for sickle cell crisis receive opioid painkillers within the first hour as treatment guidelines ...

For years, my family struggled to understand the constant, mysterious pain my younger sister and I endured. Her cries were so frequent that she earned the nickname “Holly” because she was always ...

Iron overload is prevalent among adults with sickle cell disease (SCD), according to a study presented at the annual meeting ...

Key Highlights Motixafortide effectively mobilized sufficient hematopoietic stem cells (HSCs) in patients with sickle cell disease enabling accelerated access to gene therapies 90% (9 of 10) of ...